Filter By
  • 03/21/2023

    City of Hope

    Researchers from Tempus partnered with City of Hope to study the differences in tumor microenvironment and mutational landscape of primary and metastatic colorectal cancer sites. This study utilized the whole transcriptome expression data of liver metastasis and lung metastasis in microsatellite stable colorectal cancer. The results uncovered a significant finding: a more favorable immune profile was found in lung metastasis compared to liver metastasis. This discovery has the potential to revolutioniz...

  • 01/11/2023

    University of California Los Angeles

    Researchers from Tempus partnered with the University of California Los Angeles to study the genomic landscape of small cell lung cancer (SCLC) in never smoking patients. The first and largest analysis of a rare subgroup (3-7%) of SCLC patients with no smoking history. Lung cancer in never smokers is a high unmet need due to its rising incidence over the past 20+ years. Historically, most SCLC clinical trials have e...

  • 12/07/2022

    MD Anderson Cancer Center & Dana–Farber Cancer Institute

    Researchers from Tempus partnered with MD Anderson Cancer Center and the Dana-Farber Cancer Institute to study the value of germline testing in patients with advanced cancer.  Recent studies have found that 12-17% of cancer patients carry pathogenic germline variants (genetic alterations) that translate to cancer predisposition. Despite this, many cancer patients do not meet guidelines for testing and these germline pathogenic variants go undetect...